Compare ATNM & HERZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATNM | HERZ |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.2M | 41.2M |
| IPO Year | N/A | N/A |
| Metric | ATNM | HERZ |
|---|---|---|
| Price | $1.38 | $2.61 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 223.5K | N/A |
| Earning Date | 11-14-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $90,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.11 | N/A |
| 52 Week Low | $1.03 | N/A |
| 52 Week High | $2.41 | N/A |
| Indicator | ATNM | HERZ |
|---|---|---|
| Relative Strength Index (RSI) | 47.64 | 64.92 |
| Support Level | $1.25 | $2.53 |
| Resistance Level | $1.48 | $2.66 |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 35.85 | 82.14 |
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
Herzfeld Credit Income Fund Inc is a non-diversified, closed-end management investment company. Its primary investment objective is to maximize risk-adjusted total returns, and its secondary investment objective is to generate high current income.